EXACT Sciences Corp.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US30063P1057
USD
102.26
-0.11 (-0.11%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

649.98 k

Shareholding (Sep 2025)

FII

18.10%

Held by 340 FIIs

DII

21.48%

Held by 83 DIIs

Promoter

0.50%

How big is EXACT Sciences Corp.?

22-Jun-2025

As of Jun 18, EXACT Sciences Corp. has a market capitalization of $9.91 billion, with net sales of $2.83 billion and a net profit of -$1.02 billion over the last four quarters.

Market Cap: As of Jun 18, EXACT Sciences Corp. has a market capitalization of 9,911.02 million, categorizing it as a Mid Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, EXACT Sciences Corp. reported net sales of 2,828.11 million and a net profit of -1,019.86 million.<BR><BR>Balance Sheet Snapshot: As of Dec'24, the company reported shareholder's funds of 2,402.25 million and total assets of 6,171.98 million.

View full answer

What does EXACT Sciences Corp. do?

22-Jun-2025

Exact Sciences Corporation is a mid-cap molecular diagnostics company focused on early cancer detection and prevention. As of March 2025, it reported net sales of $707 million and a net loss of $101 million.

Overview: <BR>Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of some forms of cancer, operating within the Pharmaceuticals & Biotechnology industry and classified as a mid-cap company.<BR><BR>Financial Snapshot: <BR>Net Sales: 707 Million (Quarterly Results - Mar 2025) <BR>Net Profit: -101 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 9,911.02 Million (Mid Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.66 <BR>Return on Equity: -7.34% <BR>Price to Book: 4.13<BR><BR>Contact Details: <BR>Address: 5505 ENDEAVOR LANE, MADISON WI: 53719 <BR>Tel: 1 608 2845700 <BR>Fax: 1 608 2845701 <BR>Website: http://www.exactsciences.com

View full answer

Should I buy, sell or hold EXACT Sciences Corp.?

22-Jun-2025

Who are in the management team of EXACT Sciences Corp.?

22-Jun-2025

As of March 2022, the management team of EXACT Sciences Corp. includes Kevin Conroy as Chairman, President, and CEO, and Shacey Petrovic as a Director, along with Independent Directors Thomas Carey, James Doyle, Pierre Jacquet, and Daniel Levangie.

As of March 2022, the management team of EXACT Sciences Corp. includes Mr. Kevin Conroy, who serves as the Chairman of the Board, President, and Chief Executive Officer. Additionally, the board features Ms. Shacey Petrovic as a Director, along with several Independent Directors: Mr. Thomas Carey, Mr. James Doyle, Mr. Pierre Jacquet, and Mr. Daniel Levangie.

View full answer

Is EXACT Sciences Corp. technically bullish or bearish?

07-Oct-2025

As of October 3, 2025, EXACT Sciences Corp. shows a neutral technical trend with mixed signals, including bullish weekly MACD and Bollinger Bands, but a mildly bearish daily moving average, and while it has outperformed the S&P 500 recently, it has underperformed over the past year.

As of 3 October 2025, the technical trend for EXACT Sciences Corp. has changed from mildly bearish to sideways. The current technical stance is neutral, with mixed signals across different indicators. The weekly MACD is bullish, while the monthly MACD is mildly bullish. Bollinger Bands are bullish on both weekly and monthly time frames. However, the daily moving averages indicate a mildly bearish trend. The KST and Dow Theory both show a mildly bullish stance on weekly and monthly levels. <BR><BR>In terms of performance, the stock has outperformed the S&P 500 over the past week and month, but it has significantly underperformed over the longer-term periods, with a 1-year return of -15.70% compared to the S&P 500's 17.82%. Overall, the mixed indicators suggest a cautious approach.

View full answer
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard

1

With a growth in Operating Profit of 55.51%, the company declared Very Positive results in Jun 25

  • OPERATING CASH FLOW(Y) Highest at USD 305.61 MM
  • RAW MATERIAL COST(Y) Fallen by 0.25% (YoY)
  • NET SALES(Q) Highest at USD 811.09 MM
2

Market Beating performance in long term as well as near term

stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 19,463 Million (Small Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.54

stock-summary
Return on Equity

-4.28%

stock-summary
Price to Book

7.78

Revenue and Profits:
Net Sales:
811 Million
(Quarterly Results - Jun 2025)
Net Profit:
-1 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
57.69%
0%
57.69%
6 Months
111.24%
0%
111.24%
1 Year
85.49%
0%
85.49%
2 Years
55.74%
0%
55.74%
3 Years
50.78%
0%
50.78%
4 Years
38.13%
0%
38.13%
5 Years
-31.83%
0%
-31.83%

EXACT Sciences Corp. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
21.05%
EBIT Growth (5y)
4.82%
EBIT to Interest (avg)
-17.51
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.66
Sales to Capital Employed (avg)
0.51
Tax Ratio
0.86%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0

Valuation key factors

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
4.32
EV to EBIT
-62.48
EV to EBITDA
493.99
EV to Capital Employed
3.00
EV to Sales
4.22
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-4.81%
ROE (Latest)
-7.34%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
Bearish
No Signal
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Sep 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 128 Schemes (59.89%)

Foreign Institutions

Held by 340 Foreign Institutions (18.1%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 15.99% vs 12.41% in Jun 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 92.41% vs 80.49% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "811.10",
          "val2": "699.30",
          "chgp": "15.99%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "58.00",
          "val2": "31.10",
          "chgp": "86.50%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "9.80",
          "val2": "8.40",
          "chgp": "16.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-4.90",
          "val2": "2.10",
          "chgp": "-333.33%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-1.20",
          "val2": "-15.80",
          "chgp": "92.41%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "3.40%",
          "val2": "-31.30%",
          "chgp": "3.47%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 10.36% vs 19.93% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -404.12% vs 67.27% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2,758.90",
          "val2": "2,499.80",
          "chgp": "10.36%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "23.10",
          "val2": "-76.40",
          "chgp": "130.24%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "32.60",
          "val2": "9.10",
          "chgp": "258.24%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-846.60",
          "val2": "7.10",
          "chgp": "-12,023.94%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-1,028.90",
          "val2": "-204.10",
          "chgp": "-404.12%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-69.50%",
          "val2": "-124.40%",
          "chgp": "5.49%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary

Jun'25
Jun'24
Change(%)
Net Sales
811.10
699.30
15.99%
Operating Profit (PBDIT) excl Other Income
58.00
31.10
86.50%
Interest
9.80
8.40
16.67%
Exceptional Items
-4.90
2.10
-333.33%
Consolidate Net Profit
-1.20
-15.80
92.41%
Operating Profit Margin (Excl OI)
3.40%
-31.30%
3.47%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in quarter ended Jun 2025 is 15.99% vs 12.41% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 92.41% vs 80.49% in Jun 2024

Annual Results Snapshot (Consolidated) - Dec'24stock-summary

Dec'24
Dec'23
Change(%)
Net Sales
2,758.90
2,499.80
10.36%
Operating Profit (PBDIT) excl Other Income
23.10
-76.40
130.24%
Interest
32.60
9.10
258.24%
Exceptional Items
-846.60
7.10
-12,023.94%
Consolidate Net Profit
-1,028.90
-204.10
-404.12%
Operating Profit Margin (Excl OI)
-69.50%
-124.40%
5.49%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 10.36% vs 19.93% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -404.12% vs 67.27% in Dec 2023

stock-summaryCompany CV
About EXACT Sciences Corp. stock-summary
stock-summary
EXACT Sciences Corp.
Pharmaceuticals & Biotechnology
Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Cologuard test is intended for the qualitative detection of colorectal neoplasia associated DNA markers and for the presence of occult hemoglobin in human stool. It focuses on the development of additional tests for other types of cancer. It is developing a blood-based biomarker test to aid in the early detection of lung cancer in individuals with lung nodules discovered through a computerized tomography (CT) or other scan.
Company Coordinates stock-summary
Company Details
5505 ENDEAVOR LANE , MADISON WI : 53719
Registrar Details